Key Takeaways
- Cibus reported a Q1 2026 net loss of $21.2 million, or $0.33 per share, down significantly from a $49.4 million loss in Q1 2025, with the improvement driven by the absence of a $21.0 million non-cash goodwill impairment and meaningful reductions in R&D and SG&A expenses through cost discipline initiatives.
- The Rice herbicide tolerance (HT) programme is advancing toward a targeted 2027 Latin American launch, with gene-edited traits transferred to partner Interoc's rice seeds in May 2026 following a non-binding LOI in January and an additional import permit in March; the U.S. launch has been reset to 2029 due to herbicide partner Albaugh's registration timeline.
- Cibus raised approximately $37.3 million in gross proceeds from two public equity offerings in Q1 2026: $22.3 million in January and approximately $15.0 million in March, with cash and equivalents of $30.3 million as of March 31, 2026.
- The EU Council formally adopted its first-reading position on New Genomic Techniques (NGTs) in April 2026, confirming the trilogue compromise text with the European Parliament, with a plenary vote planned for an upcoming session — a key regulatory milestone for gene-edited crop technologies.
- Cibus is targeting annual net cash usage of approximately $30 million or less in 2026, with existing cash expected to fund operations into late Q1 2027; the Sustainable Ingredients programme is ramping toward additional biofragrance scale-up orders in H2 2026.
Cibus, Inc. (Nasdaq: CBUS) reported first-quarter 2026 financial results and provided a business update highlighting continued progress in its Rice herbicide tolerance programme and Sustainable Ingredients platform. Net loss narrowed significantly to $21.2 million from $49.4 million in Q1 2025, driven by cost reductions and the absence of a prior-year goodwill impairment. The company also disclosed that it transferred gene-edited herbicide tolerance traits to Latin American partner Interoc's rice seeds in May 2026, a key step toward the targeted 2027 commercial launch.
Cibus Q1 2026 Financial Performance
R&D expenses declined $3.1 million year-over-year to $8.7 million, reflecting cost reduction initiatives. SG&A expenses fell $4.8 million to $5.1 million, including the absence of a $3.0 million litigation expense recorded in Q1 2025. There was no goodwill impairment in Q1 2026, compared to a $21.0 million non-cash impairment in Q1 2025. Net loss per share of Class A common stock was $0.33, compared to $1.34 in Q1 2025, with the improvement driven by cost reductions and the prior-year impairment charge. Cash and cash equivalents were $30.3 million as of March 31, 2026, supported by $37.3 million in gross equity proceeds raised during the quarter.
“Beyond our progress toward commercialization, we are executing well with respect to our cost discipline commitments of reducing operating expenses, and we are on track to deliver annual net cash usage of approximately $30 million or less in 2026. Combined with approximately $33 million in net proceeds raised from sales of equity during the quarter, we believe we are well-positioned to fund the advancement of our priority programs toward their near-term commercial milestones,” said Carlo Broos, CFO of Cibus.
Cibus Rice HT Programme: Latin America Advancing, U.S. Reset to 2029
The Rice herbicide tolerance programme remains on track for a targeted 2027 Latin American launch. A non-binding LOI with Interoc was announced in January 2026, establishing a commercialization framework for co-developed HT rice traits across key Latin American markets. Interoc received an additional import permit in March 2026, and Cibus subsequently transferred gene-edited traits into Interoc's rice seeds in May 2026, enabling the commencement of testing ahead of a contemplated initial market launch. The programme involves seven active customer relationships representing 5–7 million peak addressable acres and over $200 million in annual addressable royalties at peak. Discussions are also advancing with seed companies in Brazil and Argentina, and with Indian market participants through partners RTDC and AgVayā. The U.S. launch target has been revised from 2028 to 2029 in coordination with herbicide partner Albaugh, which is behind its initial registration timeline.
“We are pleased to report continued momentum across our priority programs during the first quarter of 2026. Our Rice herbicide tolerance program is advancing on multiple fronts, including meaningful progress toward commercialization with our Latin American seed partners, including initially Interoc, as we continue to eye our targeted 2027 initial launch,” said Peter Beetham, Interim CEO of Cibus.
Sustainable Ingredients, EU Regulatory Progress, and Opportunity Pipeline
The Sustainable Ingredients programme is ramping following the first customer payment in Q4 2025, with Cibus targeting additional biofragrance scale-up orders in H2 2026 and continuing development of further biofragrance products. In April 2026, the EU Council formally adopted its first-reading position on the New Genomic Techniques (NGTs) regulation, confirming the agreed trilogue text, with a European Parliament plenary vote planned for an upcoming session. Cibus also commenced work as technology partner in a DEFRA-funded UK Farming Innovation Programme targeting Light Leaf Spot disease resistance in oilseed rape, and is continuing a collaboration with the John Innes Centre on nutrient-use efficiency traits applicable to Rice, Wheat, and Canola.
1 Comment